Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979264217> ?p ?o ?g. }
- W2979264217 endingPage "1584" @default.
- W2979264217 startingPage "1584" @default.
- W2979264217 abstract ": Immunoglobulin A nephropathy (IgAN) is the most frequent glomerular disease worldwide and a leading cause of end-stage renal disease. Particularly challenging to the clinician is the early identification of patients at high risk of progression, an estimation of the decline in renal function, and the selection of only those that would benefit from additional immunosuppressive therapies. Nevertheless, the pathway to a better prognostication and to the development of targeted therapies in IgAN has been paved by recent understanding of the genetic and molecular basis of this disease. Merging the data from the Oxford Classification validation studies and prospective treatment studies has suggested that a disease-stratifying algorithm would be appropriate for disease management, although it awaits validation in a prospective setting. The emergence of potential noninvasive biomarkers may assist traditional markers (proteinuria, hematuria) in monitoring disease activity and treatment response. The recent landmark trials of IgAN treatment (STOP-IgAN and TESTING trials) have suggested that the risks associated with immunosuppressive therapy outweigh the benefits, which may shift the treatment paradigm of this disease. While awaiting the approval of the first therapies for IgAN, more targeted and less toxic immunotherapies are warranted. Accordingly, the targeting of complement activation, the modulation of mucosal immunity, the antagonism of B-cell activating factors, and proteasomal inhibition are currently being evaluated in pilot studies for IgAN treatment." @default.
- W2979264217 created "2019-10-10" @default.
- W2979264217 creator A5029584267 @default.
- W2979264217 creator A5044192397 @default.
- W2979264217 creator A5071844231 @default.
- W2979264217 creator A5074786320 @default.
- W2979264217 date "2019-10-02" @default.
- W2979264217 modified "2023-10-18" @default.
- W2979264217 title "Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?" @default.
- W2979264217 cites W1217575213 @default.
- W2979264217 cites W1554845811 @default.
- W2979264217 cites W1894073864 @default.
- W2979264217 cites W1971086200 @default.
- W2979264217 cites W1979962173 @default.
- W2979264217 cites W1987519860 @default.
- W2979264217 cites W1992884829 @default.
- W2979264217 cites W1997882896 @default.
- W2979264217 cites W1997948783 @default.
- W2979264217 cites W2000581122 @default.
- W2979264217 cites W2002051261 @default.
- W2979264217 cites W2004730097 @default.
- W2979264217 cites W2010602089 @default.
- W2979264217 cites W2012346615 @default.
- W2979264217 cites W2017568050 @default.
- W2979264217 cites W2022975241 @default.
- W2979264217 cites W2026697506 @default.
- W2979264217 cites W2030047239 @default.
- W2979264217 cites W2034844805 @default.
- W2979264217 cites W2036651304 @default.
- W2979264217 cites W2041677815 @default.
- W2979264217 cites W2045170157 @default.
- W2979264217 cites W2047971096 @default.
- W2979264217 cites W2048522842 @default.
- W2979264217 cites W2051492584 @default.
- W2979264217 cites W2055934272 @default.
- W2979264217 cites W2056583648 @default.
- W2979264217 cites W2057402675 @default.
- W2979264217 cites W2063542171 @default.
- W2979264217 cites W2068783453 @default.
- W2979264217 cites W2073322555 @default.
- W2979264217 cites W2085126429 @default.
- W2979264217 cites W2090303075 @default.
- W2979264217 cites W2096190752 @default.
- W2979264217 cites W2096977413 @default.
- W2979264217 cites W2102768836 @default.
- W2979264217 cites W2105803357 @default.
- W2979264217 cites W2107050894 @default.
- W2979264217 cites W2107238505 @default.
- W2979264217 cites W2107793847 @default.
- W2979264217 cites W2108829447 @default.
- W2979264217 cites W2110444957 @default.
- W2979264217 cites W2110648558 @default.
- W2979264217 cites W2116730178 @default.
- W2979264217 cites W2120366573 @default.
- W2979264217 cites W2122512855 @default.
- W2979264217 cites W2123917517 @default.
- W2979264217 cites W2125136564 @default.
- W2979264217 cites W2125202366 @default.
- W2979264217 cites W2125785855 @default.
- W2979264217 cites W2126486030 @default.
- W2979264217 cites W2128331580 @default.
- W2979264217 cites W2128552047 @default.
- W2979264217 cites W2133599730 @default.
- W2979264217 cites W2135143233 @default.
- W2979264217 cites W2140799427 @default.
- W2979264217 cites W2148593462 @default.
- W2979264217 cites W2150065983 @default.
- W2979264217 cites W2151689843 @default.
- W2979264217 cites W2153321574 @default.
- W2979264217 cites W2159666276 @default.
- W2979264217 cites W2162337442 @default.
- W2979264217 cites W2162989837 @default.
- W2979264217 cites W2164289320 @default.
- W2979264217 cites W2167898282 @default.
- W2979264217 cites W2169743937 @default.
- W2979264217 cites W2186629139 @default.
- W2979264217 cites W2212745154 @default.
- W2979264217 cites W2223268479 @default.
- W2979264217 cites W2313007433 @default.
- W2979264217 cites W2339791834 @default.
- W2979264217 cites W2343467869 @default.
- W2979264217 cites W2493731904 @default.
- W2979264217 cites W2510135129 @default.
- W2979264217 cites W2512099275 @default.
- W2979264217 cites W2517246046 @default.
- W2979264217 cites W2525067757 @default.
- W2979264217 cites W2546983796 @default.
- W2979264217 cites W2557141247 @default.
- W2979264217 cites W2586394131 @default.
- W2979264217 cites W2588777848 @default.
- W2979264217 cites W2589016395 @default.
- W2979264217 cites W2600347335 @default.
- W2979264217 cites W2601100087 @default.
- W2979264217 cites W2602196428 @default.
- W2979264217 cites W2614765655 @default.
- W2979264217 cites W2624171963 @default.
- W2979264217 cites W2727604819 @default.
- W2979264217 cites W2741457765 @default.